Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal use of maraviroc in clinical practice.
Soriano V, Geretti AM, Perno CF, Fätkenheuer G, Pillay D, Reynes J, Tambussi G, Calvez V, Alcamí J, Rockstroh J. Soriano V, et al. Among authors: calvez v. AIDS. 2008 Nov 12;22(17):2231-40. doi: 10.1097/QAD.0b013e3283136d95. AIDS. 2008. PMID: 18981762 Review. No abstract available.
When and how to use maraviroc in HIV-infected patients.
Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, di Perri G, Pillay D, Rockstroh J, Geretti AM. Soriano V, et al. Among authors: calvez v. AIDS. 2009 Nov 27;23(18):2377-85. doi: 10.1097/QAD.0b013e328332d32d. AIDS. 2009. PMID: 19834318 Review. No abstract available.
Resistance to novel drug classes.
Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V. Marcelin AG, et al. Among authors: calvez v. Curr Opin HIV AIDS. 2009 Nov;4(6):531-7. doi: 10.1097/COH.0b013e328331d4b1. Curr Opin HIV AIDS. 2009. PMID: 20048722 Review.
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group. Recordon-Pinson P, et al. Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7. Antimicrob Agents Chemother. 2010. PMID: 20530226 Free PMC article.
2011 update of the drug resistance mutations in HIV-1.
Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. Johnson VA, et al. Among authors: calvez v. Top Antivir Med. 2011 Nov;19(4):156-64. Top Antivir Med. 2011. PMID: 22156218 Free PMC article. Review.
HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Recordon-Pinson P, Raymond S, Bellecave P, Marcelin AG, Soulie C, Descamps D, Calvez V, Harrigan PR, Fleury H, Izopet J, Masquelier B; S AC11 Resistance Study Group. Recordon-Pinson P, et al. Among authors: calvez v. Antimicrob Agents Chemother. 2013 Feb;57(2):930-5. doi: 10.1128/AAC.02159-12. Epub 2012 Dec 3. Antimicrob Agents Chemother. 2013. PMID: 23208718 Free PMC article.
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.
Charpentier C, Lambert-Niclot S, Alteri C, Storto A, Flandre P, Svicher V, Perno CF, Brun-Vézinet F, Calvez V, Marcelin AG, Ceccherini-Silberstein F, Descamps D. Charpentier C, et al. Among authors: calvez v. PLoS One. 2013;8(1):e54381. doi: 10.1371/journal.pone.0054381. Epub 2013 Jan 18. PLoS One. 2013. PMID: 23349869 Free PMC article.
527 results